Earlier this month, Venable LLP’s Christopher Loh was highlighted in Crain’s New York Business’ 2025 special feature for notable litigators and trial attorneys. This recognition spotlights attorneys with exceptional litigation skills that have made a significant impact on the New York legal market.
“Loh works on patent trials and appeals concerning a multinational pharmaceutical company’s drug project which has benefitted millions of heart failure patients since its launch in 2015,” wrote Crain’s New York Business, referring to one of his many significant cases. The publication also touched on one of his most significant careers wins: “between October 2022 and February 2024, Loh and his team have been to trial three times in Delaware and West Virginia on the pharmaceutical company’s patents covering solid-state forms of sacubitril and valsartan, the combination that is responsible for the efficacy of the company’s blockbuster drug product.” The publication also noted that Mr. Loh has been a board member of the New York Intellectual Property Law Association for several years.
Mr. Loh practices complex patent litigation in the areas of pharmaceuticals, biotechnology, and chemistry. Over the past 20 years as lead and co-lead counsel, he has litigated and tried dozens of high-profile patent cases involving cardiovascular treatments, oncology therapies, neurologic medicines, anti-HIV drugs, and statins. Mr. Loh has argued before numerous federal district courts and the U.S. Court of Appeals for the Federal Circuit, and has won in inter partes review proceedings before the Patent Trial and Appeal Board on behalf of patent owners.
Click here to learn more about Mr. Loh’s recognition by Crain New York Business.